The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors

Theocharidou, Eleni; Papademetriou, Marianna; Reklou, Andromachi; Sachinidis, Alexandros; Boutari, Chrysoula; Γιουλεμέ, Όλγα

doi:10.2174/1381612824666181010123127

Cited by 42 publications

(42 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, high intrahepatic or circulating PCSK9 levels could increase TG storage and secretion, thus leading to a higher risk of CVD. These observations suggested the use of PCSK9 inhibitors to prevent CVD [30].…”

Section: Discussionmentioning

confidence: 93%

A dose-independent association of triglyceride levels with all-cause mortality among adults population

Huang

Liu

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

Background The relationship between triglyceride (TG) level and the mortality risk of all-cause and cardiovascular disease is not entirely consistent among adults. Methods The present analysis included adult participants from National Health and Nutrition Examination Surveys (NHANES) between the periods 1999–2014. The levels of TG were categorized into < 150, 150–199, 200–250 and ≥ 250 mg/dL respectively. Multivariate Cox regression analysis, stratified analysis and generalized additive model were conducted to reveal the correlation between TG and mortality risk. Results were presented in hazard ratio (HRs) and 95% confidence intervals (CIs). Results There were 18,781 (9130 males, mean age was 45.64 years) participants being included in the analysis. The average follow-up period was 8.25 years, where 1992 (10.61%) cases of all-cause and 421 (2.24%) cardiovascular death have occurred. In the multivariate Cox model, every 1 mg/dL raise in TG has significantly associated with all-cause mortality (HR: 1.08, 95% CI: 1.02, 1.15) but not cardiovascular mortality (HR: 1.10, 95% CI: 0.97, 1.24). When using TG < 150 mg/dL as reference, TG ≥ 250 mg/dL associated with death from all-cause (HR = 1.34, 95% CI: 1.12, 1.60; P = 0.0016 but not cardiovascular death (HR = 1.26, 95% CI: 0.85, 1.88; P = 0.2517). According to smoothing spline plots, the risk of all-cause was the lowest when TG was approximately 135 mg/dL. Conclusion TG might have a dose-independent association with all-cause mortality among adults in United States.

show abstract

Section: Discussionmentioning

confidence: 93%

A dose-independent association of triglyceride levels with all-cause mortality among adults population

Huang

Liu

et al. 2020

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…A recent review highlights that since patients with elevated cardiovascular risk require statin treatment, it would be advisable to select a specific statin that provides liver as well as cardiovascular risk reduction [19]. Other studies suggest that proprotein convertase subtilisin kexin type-9 inhibitors ameliorates NAFLD, while the association of antioxidant vitamins C and E with statin therapy in men does not bring any additional benefits [20,21].…”

Section: Resultsmentioning

confidence: 99%

Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease

Costache¹,

Garleanu²,

Aursulesei³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic fat accumulation after ruling out other causes of hepatic steatosis. The aim of the study is to identify the role of statin therapy in dyslipidemic patients with very high cardiovascular risk and NAFLD in achieving low density lipoprotein (LDL) cholesterol targets while also evaluating the changes in liver enzymes levels. This prospective study included 140 patients with NAFLD, hyperlipidemia and elevated cardiovascular risk. Serum lipids were assessed and liver function tests were performed at baseline and at 6 months follow up in 10 mg/ 20 mg daily atorvastatin treatment schedule. The results showed that total cholesterol, LDL cholesterol and triglycerides were significantly reduced at 6 months follow-up, while high density lipoprotein (HDL) cholesterol has not undergone important changes. Statin treatment significantly improved alanine aminotransferase serum levels, whereas aspartate aminotransferase levels were not significantly reduced between baseline and follow-up. Although statin therapy appears to be safe and effective for use in patients with NAFLD, an insufficient treatment is commonly observed in clinical practice, in order to avoid liver damage . NAFLD is not only a major cause of liver related morbidity and mortality, but also an independent cardiovascular risk factor, with cardiovascular mortality being the most important cause of death. Therefore, detecting and modifying risk factors without impairing liver function is desirable.

show abstract

“…The link between PCSK9 and liver steatosis is unclear. Many studies indicate that a high level of intrahepatic and circulating PCSK9 levels increase the liver lipid storage, adipose energy, and hepatic fatty acids storage, as well as triglycerides secretion and storage [99]. In 201 consecutive biopsy-confirmed NASH patients, circulating PCSK9 levels were associated with steatosis grade, necroinflammation, ballooning, and fibrosis stage [100].…”

Section: Pcsk9 Inhibitorsmentioning

confidence: 99%

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice

Perdomo

Dingianna

Escalada

et al. 2020

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only.

show abstract

The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors

Cited by 42 publications

References 0 publications

A dose-independent association of triglyceride levels with all-cause mortality among adults population

A dose-independent association of triglyceride levels with all-cause mortality among adults population

Atorvastatin in the Treatment of Dyslipidemic Patients with Very High Cardiovascular Risk and Nonalcoholic Fatty Liver Disease

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice

Contact Info

Product

Resources

About